Product How it works Pricing Blog FAQ About Contact
Sarepta Therapeutics

Sarepta Therapeutics (NASDAQ: SRPT) revenue

Sarepta Therapeutics reported revenue of $2,198m for fiscal 2025, 15.6% more than in fiscal 2024 ($1,902m). Since fiscal 2016 its revenue has grown by 40,450.4%, an average growth of 94.9% a year.

Sarepta Therapeutics has grown its revenue for 9 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record.

Revenue, in millions of US dollars5.42016154.62017301.02018380.82019540.12020701.92021933.020221,24320231,90220242,1982025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$2,198m+15.6%−$699.8m−31.8%
2024$1,902m+53.0%$218.1m11.5%
2023$1,243m+33.3%−$267.8m−21.5%
2022$933.0m+32.9%−$536.2m−57.5%
2021$701.9m+30.0%−$459.7m−65.5%
2020$540.1m+41.8%−$564.2m−104.5%
2019$380.8m+26.5%−$705.6m−185.3%
2018$301.0m+94.7%−$343.6m−114.1%
2017$154.6m+2,751.6%−$171.6m−111.0%
2016$5.4m—−$266.7m−4,920.3%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Sarepta Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Sarepta Therapeutics ranks 110th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Sarepta Therapeutics, 15.6%.

RankCompanyRevenueRevenue growth
108thEnovis$2,248m6.7%
109thICU Medical$2,231m−6.3%
110thSarepta Therapeutics$2,198m15.6%
111thConcentra Group Holdings Parent$2,163m13.9%
112thPrivia Health Group$2,123m22.3%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Sarepta Therapeutics

How much revenue did Sarepta Therapeutics make in fiscal 2025?
Sarepta Therapeutics reported revenue of $2,198m for fiscal 2025, compared with $1,902m in fiscal 2024.
How much has the revenue of Sarepta Therapeutics grown?
Between fiscal 2016 and fiscal 2025 it went from $5.4m to $2,198m: 40,450.4% more, an average growth of 94.9% a year.
What was the best year for revenue at Sarepta Therapeutics?
Of its last 10 fiscal years, fiscal 2025, with $2,198m.
Where does Sarepta Therapeutics rank in its sector by revenue?
It ranks 110th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Sarepta Therapeutics come from?
From the annual report (Form 10-K) that Sarepta Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Sarepta Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Sarepta Therapeutics: the Sarepta Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.